DOXOrubicin Hydrochloride Injection, USP, 200 mg/100 mL (2 mg/mL), For IV Use Only, Sterile, ISOT...

FDA Drug Recall #D-0412-2015 — Class III — February 11, 2015

Recall Summary

Recall Number D-0412-2015
Classification Class III — Low risk
Date Initiated February 11, 2015
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Mylan Institutional LLC
Location Rockford, IL
Product Type Drugs
Quantity 936 vials

Product Description

DOXOrubicin Hydrochloride Injection, USP, 200 mg/100 mL (2 mg/mL), For IV Use Only, Sterile, ISOTONIC SOLUTION, Caution: Cytotoxic Agent, 100 mL Multi-Dose Vial, Rx Only, Manufactured By: Onco Therapies Limited, Bangalore, 560105, INDIA, Distributed By: Amneal-Agila, LLC, Glasgow, KY, 42141, NDC 53150-317-01.

Reason for Recall

Correct Labeled Product Mispack: Ifosfamide Injection 50 mg/mL, 60 mL, correctly labeled vial may have been mis-packaged in a carton labeled Doxorubicin Hydrochloride Injection 2 mg/mL, 100 mL

Distribution Pattern

Nationwide

Lot / Code Information

Lot Number: 7801009; Exp: Apr-2015

Other Recalls from Mylan Institutional LLC

Recall # Classification Product Date
D-0601-2021 Class III Thiamine HCl Injection, USP 200 mg/2 mL (100mg/... May 3, 2021
D-1575-2020 Class I Amiodarone Hydrochloride Injection, USP, 450 mg... Aug 17, 2020
D-1576-2020 Class I Tranexamic Acid Injection, USP, 1000 mg/10 mL (... Aug 17, 2020
D-1484-2020 Class I Daptomycin for Injection, 500 mg/vial, Single-D... Jul 7, 2020
D-1271-2020 Class II Aloprim (allopurinol sodium) for Injection, 500... May 5, 2020

Frequently Asked Questions

Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.